alt

$12.20
+$0.19 (+1.6%)
Closing price October 18, 2021
24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.
Wednesday's top analyst upgrades and downgrades included Alphabet, Canopy Growth, Cinemark, Dick's Sporting Goods, Facebook, IMAX, Microsoft, Salesforce.com and SBA Communications.
Altimmune has announced additional preclinical data in regards to its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.
Thursday's top analyst upgrades and downgrades included Allstate, Bed Bath & Beyond, Simon Property, Spirit Airlines, Twitter and Under Armour.
Altimmune shares dropped on Thursday after the company announced that it had received an update from the FDA regarding its COVID-19 vaccine candidate.
Altimmune made a step forward on Tuesday with its vaccine candidate for COVID-19. Specifically, the firm entered into a manufacturing agreement the vaccine candidate.
Altimmune made some progress with its COVID-19 treatment on Monday after it announced some new funding for its trials.
24/7 Wall St. has tracked some stocks that either are defensive in general or are defying Monday's big drop because they have some aspect of their business that might be immune to daily scares or...
Altimmune shares surged on Tuesday following results from its midstage study of a intranasal influenza vaccine candidate.